The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

Eosinophilic myeloid neoplasms.

The evolving treatment paradigm in myelofibrosis.

JAK inhibition: the key to treating myeloproliferative neoplasm?

MPN blast phase: clinical challenge and assessing response.

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.